In a collaborative effort, scientists from Johns Hopkins School of Medicine and George Washington University have found that defective HIV proviruses can complicate monitoring the true viral load within patients and distract the immune system from attacking the functional virus.
In case you missed them, here are our top 5 articles for the week of April 23, 2017.
Manufacturing issues have led to a shortage of the only yellow fever vaccine licensed in the United States; now, that shortage is expected to lead to a complete depletion of available vaccine by mid-2017.
The CDC offers insight into why a rare exception to the general recommendation of either brand of MenB vaccine had been made for the Rutgers outbreak in 2016.
On World Malaria Day, the world focuses on how to eliminate malaria once and for all.
Study results presented today at the 2017 66th Annual EIS Conference provided the first statistical evidence for herd protection from the human papillomavirus (HPV) vaccine.
Although the eradication of smallpox was declared by the World Health Assembly in 1980, the deadly disease might make a comeback. The question is, will we be prepared for it?
Researchers find that children of parents or caregivers who receive the season flu shot are more likely than others to also be immunized.
While flu season in the United States continues to wane, a new study from a team of researchers details the surprising discovery of a compound that may be a powerful flu-fighter.
A new mathematical model developed by Yale School of Public Health estimates that vaccines used in tandem with interventions can potentially avert millions of HIV cases in the upcoming years.
Researchers from The University of Texas Medical Branch at Galveston (UTMB) and Instituto Evandro Chagas (IEC) have published their findings on the live-attenuated vaccine candidate in the journal Nature Medicine.
A new report released by the Centers for Disease Control and Prevention (CDC) has found that nearly half of US adults have some form of genital HPV.
In case you missed them, here are our top 5 articles for the week of April 2, 2017.
Sometimes the best surveillance tools are found in the gutter, at least according to a new study.
During a recent webcast lecture, Hana Golding, PhD from the US Food and Drug Administration described new ways to evaluate safety and effectiveness of vaccine adjuvants.
Health officials in Florida declare that they are better prepared for a potential outbreak in their state as Zika vaccinations have begun in a multi-site Phase II/IIb clinical trial of VRC705 in areas of endemic Zika transmission throughout the world.
On March 30, 2017, at the SHEA Spring 2017 Conference, Matt Linam, MD, MS, discussed strategies to prevent healthcare workers from spreading healthcare-associated infections (HAIs).
Although cases of influenza A are on the decline, a late season surge in influenza B cases are helping to extend flu season across parts of the United States.
The results of a new study have revealed that older women and African Americans are less likely to get vaccinated against influenza.
A mumps outbreak that began in the country last fall is continuing across the United States. New research suggests that even small populations of unvaccinated individuals may be fueling the outbreak.
Researchers from the University of Oxford and Janssen Pharmaceuticals believe they have demonstrated an Ebola vaccine approach that fosters immunity for up to 1 year.
Harvard T. H. Chan School of Public Health researchers report that a new rotavirus vaccine was found to be 66.7% effective.
Flu activity continues to drop across the country, but new outbreaks continue as health officials predict a flu season that could last until May in some areas.
Guidelines for the human papillomavirus (HPV) vaccine include recommendations on which populations of individuals should receive either the 2-dose or 3-dose regimen.
Hepatitis C virus is the world’s most prevalent blood-borne viral infection for which a vaccine does not exist. To eliminate HCV infection on a global scale, experts argue that vaccine development needs to become a public health priority.
